APR 14, 2015 10:28 AM PDT

Central Signaling Pathway in Lymphoma Blocked Successfully

Cancer researchers from the University of Zurich have identified a key signaling pathway in B-cell lymphoma, a malignant type of blood cancer. They demonstrate that the signaling path-way can be blocked using compounds that are already in clinical development. This finding might be extremely important for the diagnosis, prognosis and treatment of this disease in the future.
A research group headed by Corina Schmid and Anne Müller from the Institute of Molecular Cancer Research at the University of Zurich has now identified a new signaling pathway that is active in and crucial for DLBCL cells.
Diffuse large B-cell lymphoma (DLBCL) is a blood cancer and the most common malignant condition of the lymphatic system. Although DLBCL is always fatal if left untreated, the cure rate after chemotherapy combined with antibodies approaches 60 to 70 percent. Certain types of DLBCL, however, do not respond well to this standard treatment, which results in a very poor prognosis for the patients. As the biology of this type of lymphoma remains poorly understood, there is a lack of targeted therapeutic approaches. A research group headed by Corina Schmid and Anne Müller from the Institute of Molecular Cancer Research at the University of Zurich has now identified a new signaling pathway that is active in and crucial for DLBCL cells - and can be attacked efficiently using substances that are already in clinical development for other diseases.

Prognosis factor for long-term survival

The UZH researchers based their experimental approach on the hypothesis that not only genetic, but also epigenetic changes might play a crucial role in the development of lymphoma. Consequently, they analyzed the so-called methylation of DNA, an epigenetic change that controls the activity of many human genes across the genome. Altered DNA methylation is a common feature of a wide variety of tumor types, which is why it seemed likely that lymphoma cells might also use this regulatory mechanism to their advantage.

And sure enough: The bioinformatical analysis of the methylation profilesof around 70 patient samples revealed eight regions on the DNA, so-called gene loci, that were all abnormally hypermethylated and turned out to be important for the cells' survival. "Follow up experiments revealed one locus in particular that is blocked in almost all the lymphoma patients examined due to DNA methylation and therefore cannot be translated into protein," sums up principal investigator Müller.

Moreover, the cancer researchers made an astonishing discovery: In several large patient cohorts, the epigenetic silencing of this gene locus proved to be an extremely significant, negative prognostic factor for the long-term survival of DLBCL patients. "This factor could thus be important for the diagnosis and prognosis of the disease, as well as therapeutic decisions in the future," said Müller.

Inhibitors effective

The newly identified gene locus contains the genetic information for an enzyme, a phosphatase, which regulates an important signaling pathway in the lymphoma cells and is evidently essential for the tumor cells to survive. Inhibitors are under clinical development for this signaling pathway. First author Schmid and principal investigator Müller were now able to demonstrate that these are also effective against lymphoma cells in cell cultures and in an animal model: Lymphomas in mice treated with the compound grew considerably more slowly than those in untreated mice. "Interestingly, combination therapies with other established substances proved especially effective," explains Schmid, "which makes the newly described signaling pathway a promising target for future cancer treatments."

Source: University of Zurich
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 17, 2018
Cell & Molecular Biology
JUL 17, 2018
A New Player in the Control of Cell Division
Oil and water don't mix; cells can take advantage of that phenomenon, phase separation, to organize stuff without using membranes...
AUG 14, 2018
Cancer
AUG 14, 2018
Using Arsenic to Enhance Cancer Therapies Beyond Leukemia
An already existing combination of arsenic and all-trans retinoic acid is found to inhibit a key signaling pathway that exerts broad effect on oncogenic processes for some solid tumors....
SEP 05, 2018
Videos
SEP 05, 2018
Why Glioblastoma Is So Deadly
Senator John McCain passed away recently after battling brain cancer. Most forms of brain cancer are aggressive and difficult to treat because medications...
SEP 13, 2018
Cancer
SEP 13, 2018
Breast tumors can stop their own metastasis
According to the American cancer society, metastatic breast cancers or stage 4 breast cancers have 5-years survival rate of 22% which is lower than at early stages. Metastatic breast cancer...
OCT 02, 2018
Health & Medicine
OCT 02, 2018
Many Patients Are Unaware of Increased Cancer Risk
Just as recently as a few decades ago, many common health screenings were not readily available. Mammography, for breast cancer detection, wasn't ...
NOV 20, 2018
Cell & Molecular Biology
NOV 20, 2018
A Warning About Using Epigenetic Modifiers as Therapeutic Targets
In the long run, some cancer therapeutics may be doing more harm than good....
Loading Comments...